Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

906.70 -10.80 (-1.18%)

Official Closing Price Updated: 7:00 PM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Why Eli Lilly Stock Just Dropped ↗

March 17, 2026

Eli Lilly's stock price is based on growth rates that might fall short.

Via The Motley Fool

Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations ↗

March 17, 2026

HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations.

Via Benzinga

Tuesday's session: gap up and gap down stock in the S&P500 index ↗

March 17, 2026

Via Chartmill

This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock ↗

March 17, 2026

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Via The Motley Fool

Should You Avoid Pfizer? Here's the Key Risk to Watch ↗

March 17, 2026

Pfizer has reached a turning point.

Via The Motley Fool

Topics Intellectual Property

Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? ↗

March 16, 2026

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Via The Motley Fool

Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026

March 16, 2026

Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗

March 16, 2026

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Via The Motley Fool

Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial ↗

March 16, 2026

Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.

Via Benzinga

3 Companies at the Forefront of the GLP-1 Pill Wars ↗

March 16, 2026

Via MarketBeat

3 Quality Compounders to Own for Decades

March 16, 2026

Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr...

Via StockStory

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗

March 15, 2026

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

Via The Motley Fool

This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗

March 15, 2026

RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.

Via The Motley Fool

3 Stocks That Could Be Next to Announce a Stock Split ↗

March 15, 2026

Via MarketBeat

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand ↗

March 15, 2026

Via MarketBeat

Is Eli Lilly's Weight Loss Empire in Trouble? ↗

March 13, 2026

It won't be easy to knock the company off its pedestal.

Via The Motley Fool

The Great Rotation: Investors Retreat to Defensive Fortresses as 2026 Market Volatility Bites

March 13, 2026

As the first quarter of 2026 unfolds, the euphoric bull market that defined the mid-2020s has hit a formidable wall of uncertainty. A potent cocktail of geopolitical instability in the Middle East and...

Via MarketMinute

Topics Economy Stocks

Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm

March 13, 2026

In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The Real Reason Eli Lilly Is Pouring $3 Billion Into China ↗

March 13, 2026

Via MarketBeat

Kroger Shares Rise As Pharmacies Add Eli Lilly's Zepbound KwikPen ↗

March 13, 2026

Kroger shares edged higher Friday after the Cincinnati-based grocer expanded access to Lilly's Zepbound KwikPen.

Via Benzinga

The Great Pivot: How the Novo Nordisk Deal Transformed Hims & Hers (HIMS) into a Healthcare Powerhouse

March 13, 2026

As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from...

Via Finterra

Topics Economy

Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12 ↗

March 12, 2026

Eli Lilly warns that an impurity formed in compounded tirzepatide mixed with vitamin B12 could pose unknown health risks.

Via Benzinga

Should You Chase the Rally in Hims & Hers Stock Today?

March 12, 2026

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Via Barchart.com

Does This Deal Make Novo Nordisk Stock a Buy? ↗

March 12, 2026

Not many things have gone right for Novo Nordisk recently, but this is one of them.

Via The Motley Fool

Topics Intellectual Property Lawsuit

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...

Via Finterra

Topics Economy

The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot

March 12, 2026

As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers...

Via Finterra

Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years ↗

March 12, 2026

Via MarketBeat

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline ↗

March 12, 2026

AstraZeneca holds exclusive access to Abivax's data room until March 23 as Eli Lilly waits. Key Phase 3 trial results expected in June.

Via Benzinga

Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner ↗

March 11, 2026

A new battle between these longtime rival companies will likely go the same way as their previous battles.

Via The Motley Fool

Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War

March 11, 2026

The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant...

Via MarketMinute

Topics Economy Intellectual Property Lawsuit

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.